Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma

Omalizumab (Xolair) was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2003, for subcutaneous (SC) treatment of adults and adolescents (aged 12 years and older) (a) who have moderate or severe persistent asthma, (b) who have a positive skin test or in vitro reactivity to a peren...

Descripción completa

Detalles Bibliográficos
Autor principal: Curtiss, Frederic R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2005
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437644/
https://www.ncbi.nlm.nih.gov/pubmed/16300422
http://dx.doi.org/10.18553/jmcp.2005.11.9.774
_version_ 1785092577483030528
author Curtiss, Frederic R.
author_facet Curtiss, Frederic R.
author_sort Curtiss, Frederic R.
collection PubMed
description Omalizumab (Xolair) was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2003, for subcutaneous (SC) treatment of adults and adolescents (aged 12 years and older) (a) who have moderate or severe persistent asthma, (b) who have a positive skin test or in vitro reactivity to a perennial aeroallergen, and (c) whose symptoms are inadequately controlled with inhaled corticosteroids. It is associated with off-label (unapproved use) for seasonal allergic rhinitis.
format Online
Article
Text
id pubmed-10437644
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104376442023-08-21 Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma Curtiss, Frederic R. J Manag Care Pharm Editorials Omalizumab (Xolair) was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2003, for subcutaneous (SC) treatment of adults and adolescents (aged 12 years and older) (a) who have moderate or severe persistent asthma, (b) who have a positive skin test or in vitro reactivity to a perennial aeroallergen, and (c) whose symptoms are inadequately controlled with inhaled corticosteroids. It is associated with off-label (unapproved use) for seasonal allergic rhinitis. Academy of Managed Care Pharmacy 2005-11 /pmc/articles/PMC10437644/ /pubmed/16300422 http://dx.doi.org/10.18553/jmcp.2005.11.9.774 Text en Copyright © 2005, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Editorials
Curtiss, Frederic R.
Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
title Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
title_full Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
title_fullStr Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
title_full_unstemmed Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
title_short Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
title_sort selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma
topic Editorials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437644/
https://www.ncbi.nlm.nih.gov/pubmed/16300422
http://dx.doi.org/10.18553/jmcp.2005.11.9.774
work_keys_str_mv AT curtissfredericr selectivityandspecificityarethekeystocosteffectiveuseofomalizumabforallergicasthma

Ejemplares similares